Preclinical Studies on Oral SARS-CoV-2 MPro Inhibitors

Our company core values are to make a significant contribution to improving the quality of life and health of people around the world. We felt compelled to leverage our expertise in SBDD to discover an effective treatment for COVID-19. Our focused Not-for-Profit program, supported by our parent company Sosei, has employed SBDD to rapidly identify a potential clinical candidate to be used as an anti-viral treatment. This fulfilled our initial objectives, completing this stage of the program. Having successfully identified compounds potentially suitable to be used as oral agents to treat COVID-19, we are well placed to progress compounds into preclinical development, after which we anticipate the program to be progressed by interested parties with expertise in antiviral clinical development. The UK Antiviral Task Force have confirmed a qualified candidate is required for further funding to be potentially be made available. Given the urgent clinical need for antiviral agents, we are seeking funding to progress our molecules up to the potential nomination of a pre-clinical candidate. We have designed a concise program of in vitro and in vivo profiling activities encompassing tolerability, safety, selectivity and efficacy to proceed rapidly, considering the likely desired dose regimen and route of administration.